Immunomodulation in host-protective immune response against murine tuberculosis through regulation of the T regulatory cell function.

J Leukoc Biol

*Division of Molecular Medicine, Bose Institute, Kolkata, India; Department of Microbiology, Institute of Post Graduate Medical Education and Research, Kolkata, India; and Department of Microbiology, Nil Ratan Sircar Medical College, Kolkata, India

Published: November 2015


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Tuberculosis, caused by the bacteria Mycobacterium tuberculosis, is characterized by an infection in lung and spleen. In the present study, we have elucidated the mechanism by which Mycobacterium indicus pranii renders protection in in vivo Mycobacterium tuberculosis infection. We observed that Mycobacterium indicus pranii treated infected C57BL/6 mice showed a strong host-protective Th1 immune response along with a marked decrease in immunosuppressive cytokines, TGF-β, and IL-10-secreting CD4(+) T cells. This Mycobacterium indicus pranii mediated decrease in immunosuppressive cytokines was correlated with the reduction in the elevated frequency of CD4(+)CD25(+) T regulatory cells, along with the reduced TGF-β production from these T regulatory cells in tuberculosis-infected mice. This reduction in the T regulatory cell population was a result of effective modulation of STAT4-STAT5 transcription factor counter-regulation by Mycobacterium indicus pranii, which in turn, reduced the immunosuppressive activity of T regulatory cells. Thus, these findings put forward a detailed mechanistic insight into Mycobacterium indicus pranii mediated regulation of the T regulatory cell functioning during experimental murine tuberculosis, which might be helpful in combating Mycobacterium-induced pathogenesis.

Download full-text PDF

Source
http://dx.doi.org/10.1189/jlb.3A0315-114RDOI Listing

Publication Analysis

Top Keywords

mycobacterium indicus
20
indicus pranii
20
regulatory cell
12
regulatory cells
12
immune response
8
murine tuberculosis
8
regulation regulatory
8
mycobacterium tuberculosis
8
decrease immunosuppressive
8
immunosuppressive cytokines
8

Similar Publications

Resilience to stress and antibiotics, coupled with immunomodulatory behavior, uncovers Mycobacterium indicus pranii as a suitable surrogate model for tuberculosis research.

Biochem Biophys Res Commun

September 2025

Microbial Pathogenesis and Microbiome Lab, Department of Microbiology, School of Life Sciences, Central University of Rajasthan, Ajmer, Rajasthan, India. Electronic address:

Mycobacterium tuberculosis (M.tb) exhibits remarkable adaptability and persistence within host micro-environments, making tuberculosis a persistent global health challenge. Finding safe and relevant model organisms to study M.

View Article and Find Full Text PDF

(MIP), an atypical mycobacterium originally developed as an anti-leprosy vaccine, has emerged as a potent immunomodulator with diverse therapeutic applications. Despite its clinical significance, molecular mechanisms underlying MIP's immunomodulatory properties remain largely unexplored. Bacterial phosphatases are recognized as crucial virulence factors that enable pathogens to evade host defenses by modulating host immune signaling pathways, including phosphoinositide metabolism.

View Article and Find Full Text PDF

The global burden of tuberculosis, particularly multidrug-resistant (MDR) strains of Mycobacterium tuberculosis, necessitates the urgent development of novel and effective therapeutic agents. Natural products derived from plants have long served as an essential resource for drug discovery, offering structurally diverse bioactive compounds. Sphaeranthus indicus, a plant traditionally valued for its medicinal properties, has shown promise as a source of antimicrobial agents.

View Article and Find Full Text PDF

Background And Methods: While leprosy primarily affects adults, childhood leprosy poses unique challenges because of its potential to cause lifelong disabilities and stigma. This is a retrospective record review of all patients aged 15 or below, diagnosed with leprosy, who were registered at the leprosy clinic of our tertiary care center from June 2014 to December 2023.

Results: As per hospital records, 1083 leprosy cases were registered at our center during the study period.

View Article and Find Full Text PDF
Article Synopsis
  • Tuberculosis (TB) remains a leading cause of death globally, highlighting the need for new preventive strategies, including vaccines.
  • A clinical trial in India will evaluate the safety and efficacy of two TB vaccine candidates, VPM1002 and Immuvac, in 12,000 healthy individuals who live with patients diagnosed with active TB.
  • The study will measure several outcomes, including the prevention of confirmed TB cases, adverse events, vaccine effectiveness across various age groups, and immune responses post-vaccination, with approvals from relevant ethics committees in place.
View Article and Find Full Text PDF